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Abstract 
Cardiovascular diseases (CVD) are an important cause of death worldwide. Anthocyanins are a subgroup of flavo-
noids found in berries, flowers, fruits and leaves. In epidemiological and clinical studies, these polyphenols have been 
associated with improved cardiovascular risk profiles as well as decreased comorbidities. Human intervention studies 
using berries, vegetables, parts of plants and cereals (either fresh or as juice) or purified anthocyanin-rich extracts 
have demonstrated significant improvements in low density lipoproteins oxidation, lipid peroxidation, total plasma 
antioxidant capacity, and dyslipidemia as well as reduced levels of CVD molecular biomarkers. This review discusses 
the use of anthocyanins in animal models and their applications in human medicine, as dietary supplements or as 
new potent drugs against cardiovascular disease.
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Background
Cardiovascular diseases (CVD) are the number one cause 
of death each year, responsible for about 17.5 million 
(31%) of all deaths worldwide in 2012 [1]. The most com-
mon cause of CVD-related death is coronary heart dis-
ease; the second most common cause of death is stroke 
[1]. Heart failure is a clinical syndrome of complex out-
come, characterized by anomalies in the structure or 
function of the heart, impairing cardiac output [2]. The 
main causes of heart failure are associated with coronary 
heart disease, ischemia, hypertension, cardiomyopathy, 
atherosclerosis and type 2 diabetes [3].
In recent years, the use of polyphenols, including 
anthocyanins, has become common in the treatment of 
various diseases, including chronic and neurodegen-
erative conditions, as well as CVD [4]. In this regard, 
anthocyanins belong to flavonoid group that have sev-
eral pharmacologic activity, mainly antioxidant and 
anti-inflammatory actions that are associated to their 
chemical structure [5]. Anthocyanins are a subgroup of 
water-soluble pigments found in the major group of fla-
vonoids that are responsible for giving coloration that 
varies from the red to blue in the most varied plants, 
flowers, seeds, fruits and other vegetal tissues [6]. How-
ever, animals and human studies in cardiac alterations 
are still quite controversial and show a dual effect of the 
different anthocyanins and of anthocyanins-rich fruit 
extracts [7]. Thus, this review is focused on the current 
knowledge about pharmacologic actions of anthocya-
nins in alterations in cardiovascular system reported in 
human patients and animal models.
Cardiovascular disease
The most common cause of CVD is atherosclero-
sis, which involves inflammation in the vessel wall, as 
explained above [8]. It is frequently caused by the infil-
tration of low density lipoproteins (LDL) the endothe-
lium through a wall damage, once trapped in the sub 
endothelium, the LDL became more prone forming the 
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trigger the monocytes, T-cells and endothelial cells acti-
vation [11–17]. Once in the endothelium, the activation 
of the endothelial cells induce adhesion molecules, per-
meability changes, facilitating the infiltration of the mac-
rophages and T-cells and also decrease the nitric oxide 
(NO) expression, leading to an increase in the vascular 
tonus [18, 19].
This inflammatory process involves the accumulation 
of several cell types, including living and dead foam cells, 
endothelial cells and smooth muscle cells, which contrib-
ute to the formation of atherosclerotic plaques. These 
process can increase the vessel thickness, decrease the 
lumen, leading to a more turbulent blood flow [20, 21]. 
In addition, foam cells in the plaque can produce pro-
teases associated with an instability of the plaque, leading 
to a rupture of the plaque and creating an embolic pro-
cess [22, 23]. The plaque or its embolus can compromise 
the blood flow in the small vessels, leading to a diminish 
blood, causing ischemia in the organs that this vessel is 
present [22]. This process is a major cause of the com-
plications of the atherosclerosis and it is associated with 
principal CVD, such as coronary heart disease (CHD), 
stroke and peripheral arterial disease [23].
Coronary heart disease involves ischemia in the coro-
nary artery that supplies oxygen to the heart [24]. This 
condition may occurs due of the buildup of atheroscle-
rotic plaques or emboli migration in the coronary artery, 
which can lead to the decrease of the blood flow and the 
hardening of the blood vessel. This process might lead to 
a decrease in the oxygen influx to the heart, reducing its 
cardiac output or leading to cell death [25]. Stroke con-
sists in brain damage through the ischemia by a decrease 
in the blood flow caused by thrombosis or embolus [26, 
27]. In addition, another type of stroke is through a hem-
orrhagic process caused by the rupture of a brain blood 
vessel, that could the caused by a head injury or via rup-
ture of the vessels due to hypertension [28].
Peripheral arterial disease involves restricted blood 
flow in the limbs’ peripherals vessels, especially in the 
legs. This condition is usually associated with the forma-
tion of atheromatous plaques in the peripheral arteries 
or with an embolic process in those vessels, leading to 
ischemia in the limbs that results in pain and committed 
movements [29]. The chronic nature of these diseases is 
associated with a remodeling response of cardiac cells 
and cellular environment in order to reverse the del-
eterious effects caused by reactive oxygen species (ROS) 
[30–32].
The major risk factors that can influence the develop-
ment of cardiovascular diseases are: genetic predisposi-
tions, age, smoking, high cholesterol levels, high blood 
pressure, physical inactivity, unhealthy diet and dia-
betes [1]. These factors increase the likelihood of the 
onset of cardiovascular disease and they are related with 
increased oxidative stress in the body [31–35], which 
could increase the macromolecules damage. Accord-
ingly, clinical and experimental studies have shown that 
oxidative stress is associated with the pathogenesis of 
cardiovascular processes, with high production of ROS 
in relation to antioxidant factors, which exhibit low or 
unchanged activity [36–39]. In addition, the heart is an 
organ with the lower concentrations of antioxidant in the 
body, which leads to increased ROS production, so it is 
most prone to tissue and cells damage, mainly in macro-
molecules, as DNA, proteins and cell lipids [36, 37, 40].
Biomarkers and cardiovascular disease
Cellular damage to the cardiovascular system is mainly 
due to lipid peroxidation caused by the action of ROS on 
cellular lipids, such as polyunsaturated fat acids (PUFA), 
phospholipids, LDL, high density lipoproteins (HDL) and 
very low density lipoprotein (VLDL) [20]. Thereby, these 
molecules can be used as biomarker; due they are associ-
ated to prognostic of CVD.
In this regard, altered PUFA levels lead to cellular 
dysfunction and also to the production of cytotoxic 
metabolites, such as unsaturated aldehydes and malon-
dialdehyde (MDA) [41, 42]. These cytotoxic metabolites 
are produced by fragmentation and decomposition of 
lipid peroxides, especially those derived from PUFAs, 
not neutralized by antioxidants [43]. The most reactive 
unsaturated aldehyde is 4-hydroxyalkenals, a derivative of 
the peroxidation of an acyl group of the omega-6 (ω-6), 
especially the linoleic acid and the arachidonic acid. This 
substance has a large reactive capacity, causing damage 
to the mitochondrial membrane phospholipids, mainly 
cardiolipin [43], which is widely distributed in the inner 
mitochondrial membrane and plays an important role in 
the production of ATP [44–46], causing disorder mito-
chondrial homeostasis.
Others biomarkers reported are lipoproteins, LDL, 
VLDL and HDL, which are important predictors of 
CVD. In summary, studies showed that high value of 
LDL and VLDL associated with the high risk of CVD 
[47, 48], while high value of HDL are shown protective 
factor of CVD [49]. This imbalance can lead to a more 
prone environment to the oxidation of the lipoprotein 
in the damaged vessels increasing the concentration of 
oxLDL that is also associated with the high risk of CVD, 
especially atherosclerosis [30]. Lipoprotein (a) (LPa) is a 
LDL-like lipoprotein, is constituted by an apolipoprotein 
B (ApoB100) bind an apolipoprotein A (ApoA) [50, 51]. 
Increased levels of LPa is associated with an increased 
risk of CHD and atherosclerosis [52]. Its physiological 
function is not yet fully understood [53]. The LPa play 
a similar role as the oxLDL in the development of the 
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atherosclerosis as well as to the foam cell formation [54, 
55].
As inflammation is involved in induction of CVD, acute 
inflammatory biomarkers [e.g., C-reactive protein (CRP)] 
are important predictors of CVD [56, 57]. CRP is used 
to predict atherosclerosis risk [58] and it has shown in 
larger clinical trial to be a strong predictor of CVD risk 
[56, 58–60]. Some experimental data have shown CRP as 
a protective factor in the CVD, where CRP seems to bind 
LDL, blocking its oxidation, this process prevents the 
macrophages to differentiate into foam cells [61]. How-
ever, some experiments also shows that CRP activate the 
complement system in the atherosclerosis site, by biding 
to phosphocholine, so inhibiting the lectin complement 
pathway [57]. Despite the controversial function of CRP 
in the CVD, it still is a strong marker for CVD risk [57].
Cardiovascular diseases represents a major public 
health problem in the modern world, affecting millions 
of people worldwide. Its mechanism is summarized in 
Fig.  1. Today we have good predictor for this disease, 
associating its risk factor and biomarkers is possible to 
have an idea if a person will develop a CVD. One of the 
greatest problem is to prevent and to treat those diseases, 
being important the investigation of new therapeutic 
agents. The dietary polyphenols, mainly anthocyanins, 
have shown some cardio protector activity, as will be dis-
cussed below.
Anthocyanins
Anthocyanins are a subgroup of water-soluble pigments 
found in the major group of flavonoids that are responsi-
ble for colors ranging from red to blue in plants, flowers, 
seeds, fruits and other vegetal tissues [62], such as açaí 
(Euterpe oleracea) [63], strawberry (Fragaria  ×  anana-
ssa) [64], elderberry [65], chokeberry (Aronia mel-
anocarpa) [66, 183–185]. Thus, almost all species of 
angiosperms present anthocyanins [62]. They are simi-
lar molecules that have a benzoic ring linked to a non-
benzoic ring with an oxygen atom inside in a condensed 
way. There is yet another benzoic ring linked to those 
first two by a carbon–carbon bound (C–C), this structure 
is known as 2-phenyl benzopyrylium cation or flavylium 
ion [6]. In each of those rings, named A-, B- and C-rings, 
there are seven different radicals in all of each valences 
and the variation of those said radicals that will differ the 
anthocyanidins, as shown in Fig. 2.
Anthocyanins, the most common form of anthocya-
nidins in plants [67], contain the glycosylated flavylium 
ion [6]. There are more than 300 known anthocyanidins 
[68]; however, there is up to 8000 different possibilities of 
anthocyanins, including the different types of anthocya-
nidins and the glycosylated part [69].
Anthocyanin mechanism of action
Nowadays, the use of polyphenolics, including antho-
cyanins, has been important in the treatment of chronic 
disease, such as CVD [4]. The pharmacologic action of 
these polyphenolics have been associated to the chemi-
cal structure of these compounds, as shown in Fig.  1. 
Regarding to anthocyanins, several studies have shown 
their beneficial effects on CVD, inhibiting the inflamma-
tory process, the endothelial dysfunction and NO pro-
duction [70, 71]. The major proposed action mechanisms 
of fruits/flowers extracts or isolates anthocyanins are 
described below.
Antioxidant action of anthocyanins
The antioxidant potential of anthocyanins is regulated by 
differences in chemical structure, which depend on the 
number and position of hydroxyl groups (⋅OH), conju-
gation groups, the degree of glycosylation and the pres-
ence of donor electrons in the ring structure, due to the 
ability of the aromatic group to endure the disappear-
ance of electrons, as shown in Fig.  1 [72, 73]. Although 
antioxidant activity is greatly dependent on the chemical 
structure of anthocyanins, some studies report that they 
do not possess similar activity levels for scavenging ROS/
reactive nitrogen species (RNS) [73, 74].
Oxidative stress constitutes a unifying mechanism of 
tissue injury leading to CVD. It occurs due an imbalance 
between the generation of ROS and RNS and the antioxi-
dant defense systems in the body. These reactive species 
attack biomolecules such as lipids, DNA, and proteins 
enhancing the previously established tissue damage, as 
well as triggering cell death pathways [75, 76]. ROS are a 
family of highly reactive species formed either enzymati-
cally or no enzymatically in mammalian cells. They can 
cause cell damage either directly or through behaving as 
intermediates in diverse cell signaling pathways [76]. In 
the intact heart, the production of ROS occurs in three 
principal cells, endothelial cells, cardiomyocytes and neu-
trophils, or to pathway of the auto-oxidation of catecho-
lamines [77–79]. Those free radicals are by-products of 
endogenous compounds or xenobiotics, provided from 
mechanisms like of the electron transport chain, nicotina-
mide adenine dinucleotide phosphate (NADPH) oxidase, 
xanthine oxidase (XO), metabolism of the arachidonic acid 
and cytochrome P-450 (CYP) [79]. Other sources of ROS 
may be reactions involving peroxisomal oxidases [80, 81] 
CYP enzymes [79, 82], NADPH oxidases [79, 82], or XO 
[83]. Some work also elucidate that the production of ROS 
can be resulted of the mechanism of the monoamines oxi-
dases and proteins p66 [70, 84]. However, studies highlight 
that the major sources of ROS production in CVD are: 
mitochondrial, XO and NADPH oxidase pathways [84].
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Antioxidant action of anthocyanins in ROS production
In anthocyanins, the number of free ⋅OH around the 
pyrone ring and the higher number of ⋅OH groups scat-
tered throughout the molecule’s structure determine the 
potency of its antioxidant activity [85]. In this regard, the 
number of ⋅OH in the presence of C3′ and C4′ position 
in ring B and C3 of the C ring flavonoid basic nucleus 
appears to be the major structural requirement for the 
Fig. 1 Cardiovascular diseases: risk factors and molecular biomarkers. The main risk factors of cardiovascular disease are related to the oxidative 
stress, generating markers that are used to predict cardiovascular risk
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anthocyanins, inhibition the oxidative injury of the 
endothelial cells and the intracellular activity of free radi-
cals. Moreover, the presence of methylation at positions 
(C3′, C4′e C3) reduce these effects. Comparing substi-
tutions of different sugars, anthocyanins having glucose 
and galactose monosaccharides have higher antioxidant 
benefits regarding those containing disaccharides [86, 
87].
The antioxidant mechanisms of the anthocyanins typi-
cally include the suppression of reactive species forma-
tion, through enzyme inhibition or the sequestration of 
trace elements involved in the production of free radicals 
[88]. It is proposed that flavonoids interrupt the chain 
reaction of free radicals by donating hydrogen atoms to 
the peroxyl radical, forming a flavonoid radical. The fla-
vonoid radical then reacts with the free radical ending, 
thus, propagation chain reaction [89]. In addition, antho-
cyanins have an anti-peroxidative activity, as showed in 
some studies in that various flavonoids inhibited the lipid 
peroxidation of rat liver cell membrane induced both by 
ascorbic acid-Fe2+ system and arachidonic acid [90, 91].
Studies on the antioxidant effect have revealed that 
these anthocyanins act by different mechanisms, such 
as capturing free radicals and/or anions, inhibiting XO, 
chelating metal ions, targeting arachidonic acid and 
adhesion of molecules.
Capturing free radicals and/or anions
The phenolic structure of anthocyanins allows for the 
donation of a proton belonging to a free radical, which 
regenerates the acyl glycerol molecule and stops oxida-
tion by free radicals. Thus, the phenol derivatives are 
transformed into free radicals and can stabilize and prop-
agate without promoting oxidation reactions [92]. Along 
with other flavonoids, anthocyanins can directly remove 
the molecular species of active oxygen, including hydro-
gen peroxide, singlet oxygen, and superoxide, ⋅OH and 
peroxyl radicals [93, 94].
Inhibition of xanthine oxidase
Several studies have reported the inhibitory action of 
anthocyanins in the XO pathway. In this regard, one of 
the methods used to evaluate this effect in XO activ-
ity is measure the uric acid production, as described by 
Cos et  al. [95] and Alves et  al. [96] showed the inhibi-
tory action of flavonoids on XO activity through of the 
increased uric acid concentration. They also demon-
strated that the ⋅OH in C-5 and C-7 positions in flavo-
noids lead an enhanced XO inhibitory action, while the 
presence of these groups bonded at C-6 and C-3 consid-
erably reduces this effect [97].
Some studies also showed that the replacement of ⋅OH 
with sugars in the structure of anthocyanins also could 
inhibit XO activity in relation to aglucone anthocyanins, 
indicating that steric interactions reduce the inhibitory 
effect on XO. Other determining factor to XO inhibitory 
action is the planarity of anthocyanins, which must con-
tain the double bond between C-2 and C-3 positions and 
B ring that is coupled by conjugation to A and C rings. 
Saturation of this double bond conjugation and destroy 
the coplanarity of the anthocyanins are responsible for 
inhibitory effect on the XO enzyme. In this regard, Acq-
uaviva et  al. [98] reported the effects of cyanidin and 
cyanidin 3-O-β-d-glucoside on DNA cleavage, on their 
free radical scavenging capacity and on XO activity. 
Thus, cyanidin and cyanidin 3-O-β-d-glucoside showed 
a protective effect on DNA cleavage, a dose-dependent 
free radical scavenging activity and an inhibition of XO 
activity.
Chelating metal ions like iron or copper
Oxidative stress can be associated with iron storage pro-
tein, ferritin or heme proteins, which contribute to the 
initiation and propagation of lipid peroxidation. How-
ever, some investigators have questioned this claim, 
suggesting that Fe2+ and Fe3+ may be involved in iron-
oxygen complex, acting as a pro-oxidant. In this context, 
the anthocyanins with their 3′,4′-dihydroxy groups can 
quickly chelate metal ions to form stable anthocyanin-
metal complexes [99]. In addition, they also inhibit the 
oxidation of LDL induced by copper or by peroxyl radical 
[100–104].
Another important factor is that polyphenols with 
a catechol group can also bind metal ions. Bittar et  al. 
[105] showed that anthocyanin analogues had a cat-
echol group, which is associated to metal-binding 
and antioxidant properties. A study reported that the 
Fig. 2 Structural body of anthocyanidins. Structural body of antho-
cyanidins, ion flavilium composed of an aromatic ring (A) condensed 
with a non-aromatic ring (C) and another aromatic ring (B) forming a 
carbon–carbon bonding
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anthocyanin, eggplant peels the delphinidin-3-(p-
coumaroylrutinoside)-5-glucoside (nasunin), has anti-
oxidant potent activity by chelating ferrous-dependent 
mechanism. The findings suggest that nasunin is a potent 
O(2) scavenger and has protective activity against lipid 
peroxidation [106]. A chelating metal indirect mecha-
nism of flavonoids was reported by Viana et al. [107] who 
demonstrated in vitro system that flavonoids prevent the 
oxidation of LDL, catalyzed by copper, the decrease in 
the consumption of vitamin E.
Others mechanisms of anthocyanins not yet elucidated 
is the inhibition of apoptosis of macrophage induced by 
oxidized LDL. Chang also demonstrated the ability of 
anthocyanins to be incorporated into the membrane 
and cytosol of endothelial cells, protecting them tightly 
against the oxidative damage induced by hydrogen per-
oxide and the 2,2′-azobis(2-amidinopropane) dihy-
drochloride [108, 109]. Anthocyanins protect the skin 
against ultraviolet radiation (UV) [110], helping to pre-
vent photo-aging, combat hyperpigmentation induced by 
ultraviolet radiation, as well as have the ability to inhibit 
the synthesis of melanin by inhibiting the activity enzyme 
tyrosinase [111]. This strong antioxidant activity is on 
the one hand the result of electron deficit in its chemi-
cal structure, and, secondly, the structure conjugate of 
anthocyanins, allowing the electronic delocalization 
leads to obtaining more stable radical products requiring 
further studies ratio structure and activity is acting in the 
inhibition of this enzyme.
Regarding to CVD, in vitro and in vivo studies showed 
that anthocyanins inhibit the oxidative stress involved in 
the atherosclerotic process [112]. Since several mecha-
nisms may be involved in this process, as the ability of 
anthocyanins inhibit LDL oxidation [113] and reduce 
oxidative injury of vascular endothelial cells [114]. The 
underlying mechanism remains unclear.
Arachidonic acid targeting: phospholipase pathways
Another pharmacologic effect of anthocyanin is its anti-
inflammatory action in several disease, which is widely 
reported in studies about biomarkers of inflammation. In 
this context, lipid mediators derived from arachidonic acid, 
as prostaglandins produced via cyclooxygenase (COX)-2 
and leukotrienes via lipoxygenases (LOX) are important 
targets of anthocyanins [103, 104]. Dreiseitel et  al. [115] 
showed that cyanidin, malvidin, peonidin, petunidin and 
delphinidin were the most potent inhibitors of secretory-
phospholipaseA2 (PLA2). PLA2 is a superfamily of ester-
ases secreted by cells membranes that catalyze hydrolysis 
of sn-2 position of membrane glycerophospholipids to gen-
erate arachidonic acid as well others free fatty acids [4], 
precursor of prostaglandins and leukotrienes [106]. Some 
members of the PLA2 family is lipoprotein-associated 
PLA2 and secretory PLA2 [107], both the modified struc-
tures, complexed with LDL or HDL, have been shown to 
associate with oxLDL and activating various inflamma-
tory pathways for atherogenesis and plaque rupture [108]. 
In vitro studies, anthocyanins also showed different degrees 
of COX-1 and COX-2 inhibition that were dependent on 
the number of free ⋅OH [109–113]. COX are enzymes 
required for the conversion of n-6 fatty acids, mostly ara-
chidonic acid, to prostanoids that play an important role in 
inflammation [116]. Cyanidin has high inhibitory activity in 
these enzymes [109, 114].
Another important enzyme inhibited by anthocyanins 
is LOX. In this sense, Knaup et  al. [117] tested many 
distinct anthocyanins and the Dp-3-O-glucoside and 
Dp-3-O-galactoside showed better LOX inhibition, due 
to combinations of radical scavenging, binding to the 
hydrophobic site of the LOX and/or an interaction with 
hydrophobic fatty acid substrate [118]. LOX uses arachi-
donic acid as substrate, catalyzing four different reac-
tions such as 5S, 12R, 12S or 15S oxygenation [117]. The 
oxygenated substrates of these enzymes initiate biologi-
cal reaction, activate cellular signaling through surface 
receptors or are metabolized to potent lipid mediators 
[119]. Kuhn et al. [120] highlighted the LOX influences in 
inflammatory process, atherogenesis, and hypertension.
NF‑κB, TNF‑α pathways targeting and adhesion molecules
Chronic inflammation is typical in vascular endothelial 
dysfunction triggered by the activation of certain fac-
tors such as nuclear factor (NF)-κB, which is functionally 
dependent on the cellular redox state. In this context, the 
tumor necrosis factor (TNF)-α activates NF-κB signaling 
transduction what is considered involved in the patho-
genic of atherosclerosis [121]. Thereby, anthocyanins 
also act inhibiting NF-κB and NF-κB -dependent media-
tors. Paixão et al. [105] showed that malvidin-3-glucoside 
could suppress pro-inflammatory mediators through 
of the NF-κB inhibition in bovine arterial endothelial 
cell. Another research showed that malvidin inhibited 
the TNF-α, and it blocked the MCP-1, ICAM-1 and 
VCAM-1 expression induced by TNF-α [122]. These 
authors also reported that the malvidin inhibited the 
p65-subunit NF-κB, suggesting that malvidin could block 
the degradation of IkB, a cytoplasm protein that regulates 
NF-κB. Others anthocyanins also have been reported 
to inhibit the TNF-α [123–126] and NF-κB [127], as 
cyanidin-3-O-glucoside. Limtrakul et  al. [128] evaluated 
the anti-inflammatory effect of black rice whole grain 
extracts (BR-WG-P), rich in anthocyanin constituents, 
according to their finds BR-WG-P could inhibit NF-κB 
and AP-1, pathways that controls pro-inflammatory 
mediators such as inducible NO synthase (iNOS), COX-
2, interleukin (IL)-6 and TNF-α.
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NO targeting
Vasodilation is a process to increase blood flow through 
endothelial cells that release vasodilators such as pros-
tacyclin and NO, which has great influence on vascu-
lar tone [22]. It is also released by endothelium cells 
molecules that opposite NO function called vasocon-
strictor molecules such as endothelin-1 (ET-1) and 
angiotensin-2 [21, 22]. The anthocyanins also have 
inhibitory action in vasodilators. In this regard, the 
cyanidin-3-glucoside (C3G) showed to be an ONOO⋅ 
scavenger and inhibitor of various ONOO· induced oxi-
dative process, such as DNA strand breakage, tyrosine 
nitration and suppression of mitochondrial respiration 
[129]. Another study using extract of blackberry, which 
has 88% of C3G of its total anthocyanin content, data 
showed that this extract suppressed the NO produc-
tion, suggesting that this effect was due to majority of 
C3G in the extract [130]. Others studies related that the 
C3G inhibited the nitric oxide [131, 132]. C3G, delphi-
nidin-3-glucoside and pelargonidin-3-glucoside also 
were tested and they protected the ONOO· induced 
apoptotic on endothelial cells [133]. All anthocyanin 
prevented ONOO· injury on endothelial cells through 
disrupting mitochondrial apoptotic pathway and inhibi-
tion of the Bax nuclear translocation [133]. Martin et al. 
[134] showed that delphinidin and cyanidin led down-
regulation of the eNOS and ET-1 expression, preventing 
endothelial cells apoptosis.
Induction of Nrf2 transcription triggering heme oxygenase‑1 
expression
Some studies have also reported that anthocyanins 
had a stimulatory effect in the nuclear factor erythroid 
2-related factor (Nrf2) pathway. The Nrf2 is an induc-
ible transcription factor with a high sensitivity to oxida-
tive stress located in the cytoskeleton, which is widely 
expressed in organs with hyperoxia consumption, such as 
the muscle, heart, vasculature, liver, kidney, brain, lung, 
skin, and digestive tract [135, 136]. In humans, Nrf2 pro-
tein has 605 amino acids, a molecular weight of 66 kDa 
and contains a basic region leucine zipper-type (bZIP) 
motif in its C-terminal domain [135, 136]. Under normal 
conditions, Nrf2 is associated to an actin-bound protein, 
Keap1, but upon exposure to chemicals (often electro-
philes) or ROS, the ubiquitin proteasome pathway (ubiq-
uitin E3 ligase) promotes the Nrf2 degradation, thus the 
stabilized Nrf2 accumulates in the nucleus and transacti-
vates the antioxidant response elements (ARE)-regulated 
target gene [135–137]. In this regard, Nrf2 is a key regu-
lator of endogenous antioxidant and protective defense, 
including glutathione S-transferase (GST) and peroxidase 
(GPx), NAD(P)H: quinoneoxidoreductase1(NQO-1), 
hemeoxygenase-1(HO-1), glutamate cysteine ligase 
(GCL), γ-glutamylcysteine synthase (GCS) and glucose 
6-phosphate dehydrogenase (G-6PDH) [135, 136, 138].
Therefore, the Keap1-Nrf2 system protects cellular 
proteins and DNA from oxidative damage caused by ROS 
and electrophiles, due an upregulation of antioxidant 
enzymes and decreased sensitivity to oxidative stress 
damage related to inflammatory reactions, respiratory 
system and, cardiovascular diseases [135, 136]. The phys-
iological oxidative stress levels, related to CVD, activate 
weakly the Nfr2 [135]. Thus, pharmacological interven-
tions to enhance the efficiency of the induction of Nfr2 
provide homeostatic mechanisms to increase its antioxi-
dant activity.
In this regard, Soreti et al. [139] showed that endothe-
lial progenitor cells treated with high and low concen-
trations of C3G produced HO-1 in a dose-dependent 
manner. Therefore, these authors suggested that the 
endothelial protection mechanism of C3G could also be 
associated with HO-1 induction, antioxidant enzyme 
regulated by Nrf2. In addition, another study with Aronia 
melanocarpa showed high levels of HO-1 in endothelial 
progenitor cells cultured with angiotensin II, and also 
the enhanced level of Nrf2 in a concentration-dependent 
manner [140]. Thus, an important mechanism of antho-
cyanins’ antioxidant activities could be due not only by 
its polyphenols but also with the activation of the Nrf2 
that promotes the induction of HO-1. Recently, Pantan 
et al. [141] reported that C3G anthocyanin may be used 
in combination with low doses of statin, which may be 
alternative treatment for atherosclerosis due both to the 
anti-inflammatory and antioxidant properties attenuat-
ing oxidative stress. Data showed the synergistic effect of 
atorvastatin and C3G enhanced the activation of the Nrf2 
signaling pathway, promoting the activation heme oxyge-
nase (HO-1).
Studies in animal models involving anthocyanins 
in cardiovascular diseases
Animal models have proven successful in validating 
hypotheses with high accuracy when compared to human 
trials. The compilation of the animal models in the next 
sections is showed in Table 1.
Rat model
As described above, anthocyanins have various pharma-
cologic actions. Here, we report several studies involv-
ing the cardiovascular system performed in rat models. 
Shaughnessy et  al. [142] showed the inhibition of sys-
tolic blood pressure (SBP) in spontaneously hyperten-
sive stroke-prone rats (SHRSP) after the treatment with 
blueberry-enriched diet (BB). The results demonstrated 
that after 8 weeks of treatment with BB, the SHRSP + BB 
group presented SBP of 178  ±  15  mmHg, while the 
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control group (SHRSP) has SBP of 216  ±  11  mmHg. 
These authors concluded that food intake as BB may be 
used to combat hypertension and cardiovascular dis-
ease prevention. Prior studies also have demonstrated a 
reduction in blood pressure after diet rich in antioxidants 
[143–147].
The consumption of a BB diet for 7 weeks was used by 
Kalea et  al. [148] to investigate vascular reactivity. The 
vasoconstriction induced by l-phenylephrine (Phe) in 
aorta rings was lowest in groups fed with BB, as well as 
antagonism of NO synthase caused a significant increase 
in vasoconstriction in both groups. NO dependent vaso-
dilation via endothelium induced by acetylcholine was 
higher in the experimental group. The BB diet showed 
vasodilator and vasoconstrictor effect on the aorta and 
this was dependent of the NO metabolic pathway. Other 
findings also observed vasodilator effect of anthocyanins 
in the endothelium-dependent relaxation [149–152].
An anti-atherogenic effect of grape–bilberry was dem-
onstrated by Graf et  al. [153], who reported that treat-
ment with anthocyanin-rich grape–bilberry juice, at 
doses of 1.551  mg of anthocyanins/L, reduced total 
cholesterol and triglyceride levels in the treated animal. 
Moreover, these authors investigated the distribution of 
fatty acids in plasma, and they observed decreased satu-
rated fatty acids and increase of the long-chain n3-PUFA. 
Thus, the intake anthocyanins-rich juice of had ben-
eficial effects in preventing atherosclerosis by improving 
endothelial function and serum lipid.
The lipid profile and oxidative stress were analyzed by 
Mohamed et  al. [154] in animals treated with a hyper-
caloric diet supplemented at different concentrations 
(2.5, 5 and 10%) with two species of blackberry (Morus 
alba L. and Morus nigra) over the course of 4 weeks. In 
relation to oxidative stress, the authors observed a reduc-
tion in MDA and NO levels in the Morus alba L. group 
(5 and 10%) and the Morus nigra group (2.5, 5 and 10%). 
These fruits also increased the total antioxidant capac-
ity (TEAC) at all evaluated concentrations of blackberry 
fruit. Regarding to lipid profile, there was significant 
reduction of total cholesterol, triacylglycerols, LDL and 
VLDL and increase in HDL in plasma in relation to 
control group. The consumption of blackberries rich in 
natural antioxidant could prevent the risk of onset of car-
diovascular diseases, reducing the lipid profile and the 
oxidative stress.
Sankhari et al. [155] used an atherogenic animal model 
to evaluate the effect of purple cabbage (Brassica olera-
cea L.) on oxidative stress in heart and in liver. During 
8  weeks, the animals received an atherogenic diet and 
oral supplementation of the anthocyanin-rich extract 
of purple cabbage (100  mg/kg/day). The results of the 
ingestion of anthocyanins by atherogenic rats showed 
effective decrease of glutathione (GSH) and elevation of 
the HDL-c level in serum, as well as the decrease of the 
cardiac (creatinine kinase, creatinine kinase-MB, lactate 
dehydrogenase) and hepatic markers (aspartate transami-
nase and alanine transaminase) compared to atherogenic 
rats. In the oxidative stress in cardiac and hepatic tis-
sues, the result demonstrated increase of the activities of 
superoxide dismutase (SOD), Catalase, GSH and ascor-
bic acid. The levels of lipid peroxidation had significant 
decrease in the studied tissues, suggesting the cardiopro-
tector and hepatoprotector effects of the anthocyanins.
Zawistowski, Kopecand and Kitts [156] studied the 
onset of hypercholesterolemia in Wistar rats treated with 
an atherogenic diet, with the supplementation of a black 
rice (Oryza sativa L.)-derived, anthocyanin-rich extract 
Table 1 Effect of anthocyanins in animal models
SBP systolic blood pressure, PUFA polyunsaturated fatty acids, LDL low-density 
lipoprotein, VLDL very low density lipoprotein, HDL high-density lipoprotein, 
MDA malondialdehyde, CRP C-reactive protein, GSH glutathione, ApoE 
apolipoprotein E, TNF-α tumor necrosis factor-α
Model Pharmacological effect References
Rats ↓ SBP [142–147]
Vasodilation [148–152]
↓ Total cholesterol [153, 156]
↓ LDL [154, 156, 158]
↓ VLDL [154]
↑ HDL [154, 155]




↓ Lipid peroxidation [155]
Mice ↓ Total cholesterol [147, 162–165]
↓ LDL [163]
↑ HDL [163, 164]
↓ Total triglycerides [147, 164, 165]
↓ Lipid peroxidation [163]
↓ Atherosclerotic lesions [161, 166]
↓ TNF-α [166]
↓ NF-κB [166]
Rabbits ↓ Total cholesterol [170]
↓ LDL [170]
↑ LDL [169, 172]
↓ VLDL [169]
↑ HDL [170, 171]
↓ Total triglycerides [172]
↓ MDA [168]
↓ CRP [170]
↓ GSH [170, 172]
↑ ApoE [170]
↓ Atherosclerotic lesions [172]
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(3% w/w) for 10  weeks. After this period, the treated 
groups with just the atherogenic diet presented accentu-
ate hypercholesterolemia. The results analyzed showed 
that the addition of black rice extract was capable to 
decrease the total cholesterol, LDL-c and triglycerides 
levels. However, there was not a significant difference 
in the levels of HDL-c. It was analyzed the decrease of 
total cholesterol concentration in the liver of the treated 
group, but there was not any significant difference in the 
heart or aorta. Yang et  al. [157] also analyzed the sup-
plementation with anthocyanin extract from black rice 
(5  g/kg) during 20  weeks, showing the reduction of tri-
glycerides and the absence of significant difference of 
total cholesterol, LDL-c and HDL-c in the groups. This 
data showed that the ingestion of black rice was promi-
sor in the reduction of the lipid profile in rats with 
hypercholesterolemia.
Valcheva-Kuzmanova et  al. [158] showed the anti-
hyperlipidemic effect of Aroniamelanocarpa fruit juice 
(AMFJ) at doses of 5, 10 and 20 mL/kg, which was admin-
istered over the course of 30 days in rats treated with a 
hyperlipidemia diet. The serum levels of total cholesterol 
and LDL-c found lower levels in all the tested doses when 
compared with the control. Regarding the concentra-
tion of triglycerides, only the dose of 20 mg/kg of AMFJ 
able inhibit triglycerides. Yet, the experimental groups 
did not show significant difference in HDL-c. The results 
point to a possible heart protective effect of AMFJ, once 
it has in its composition phenolic compounds that might 
have antioxidant action, for example, the anthocyanins. 
Hypolipidemic and of oxidative stress effects were also 
shown in other studies [159, 160].
Mouse model
Mauray et  al. [161] also performed a study with apo 
E-deficient mice. The mice were treated with a diet of 
anthocyanin-rich bilberry extract (0.2 g/kg) or fermented 
blueberry extract (0.2  g/kg) during 16  weeks. They 
observed reduction in atherosclerotic lesions in anthocy-
anin-rich bilberry extract (15%) and fermented blueberry 
extract groups (36%). The concentration of thiobarbituric 
acid-reactive substances (TBARS), the plasma antioxi-
dant capacity, total cholesterol and triacylglycerol were 
not showed significant difference between the treated 
groups. In 2012, Mauray et al. [162] redid the treatment 
with apo E-deficient mice, however using only anthocy-
anin-rich bilberry extract and a control group, during 
2 week. The results did not show significant difference in 
triglycerides concentration, plasma antioxidant capacity 
and level of HDL/LDL, corroborating with results found 
in 2009 research. However, total cholesterol levels were 
reduced due to ingestion of anthocyanin-rich bilberry 
extract. Both studies showed that the anthocyanin extract 
was not able to reverse lipid index and oxidative stress, 
but there may be some fermented anthocyanins bioactive 
compounds to prove its positive results.
In the same year, Wang et al. [163] used two treatment 
models to investigate the effect of C3G on endothelial 
dysfunction and atherogenesis in Apo E-deficient ani-
mals. In the prevention model, the animals were treated 
with doses of C3G (2  g/kg) and a cholesterol-rich diet 
during 8  weeks. This model showed reduction of total 
cholesterol levels and LDL-c, as well as high HDL-c level 
in experimental group; however, there was no significant 
difference in triglyceride levels. The ingestion of C3G 
promoted augmentation of relaxation of acetylcholine-
induced aortic rings, and reduction of atherosclerotic 
lesion in 54%. In addition, theses authors also showed 
reduction of cholesterol concentration, 7-ketocholes-
terol (7-KC) and 7-KC-cholesterol, and increase of ATP-
binding cassette transporter G1 protein (ABCG1) in 
aortic C3G animals. The oxidative stress parameters ana-
lyzed showed reduction of SOD and lipid hydroperoxide 
in the treated group. Mice fed with C3G had increased 
phosphorylation of eNOS SER1177, leading the increase 
of concentration of nitrite and nitrate, and lower cGMP 
in the aorta. Thus, the treatment showed recovery in 
endothelial dysfunction, reduced atherosclerotic lesion, 
more ABCG1 expression, lowering of cholesterol level 
and 7-KC and an increase in cGMP concentration com-
pared to the control. However, no significant difference 
in triglyceride levels.
Zhang et  al. [147] obtained similar results in diabetic 
apolipoprotein E-deficient mice after the animals con-
sumed C3G (0.2%) for 6 weeks. The consumption of C3G 
improved the impairment of endothelial function, lipid 
profile and prevention or treatment of diabetic vascular 
complications. Xia et al. [164] also studied anthocyanin-
rich extract from black rice and evaluated the lipid pro-
file in animals. The animals were treated with 300 mg/kg 
of the extract during 20 weeks and showed reduction of 
cholesterol, triglycerides, HDL-c levels in serum in com-
parison to control group. Wu et  al. [165] verified that 
the doses of 40 and 200 mg of the purified anthocyanins 
from mulberry (MACN) during 12 weeks was enough to 
reduce the levels of cholesterol, triglycerides and total 
lipids when in comparison to high-fat diet-treated group, 
acting as an important heart protector.
Anti-atherogenic effects and the reduction in inflam-
matory activity were analyzed by Wang et al. [166], who 
demonstrated the inhibition of TNF-α, vascular cell 
adhesion molecule 1 (VCAM-1), intercellular adhesion 
molecule 1 (ICAM-1) and nuclear factor-κB (NF-κB), 
demonstrating that ingesting protocatechuic acid can 
reduce the pro-inflammatory factors responsible for the 
worsening of atherosclerosis. Reduction of inflammation 
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by anthocyanins was also reported by Seymour et  al. 
[167].
Rabbit model
Yamakoshi et  al. [168] evaluated supplementation with 
proanthocyanidin-rich extract from grape seeds (1% 
w/w) in cholesterol-fed rabbits. The experimental group 
showed a lower hydroperoxide and MDA levels com-
pared to control group. However, did not affect the 
lipid profile, suggesting the antioxidant activity of the 
polyphenol.
Finné Nielsen et  al. [169] studied the effects of black 
gooseberry juice (BGJ) and anthocyanin purified 
from black gooseberry juice (APE) extract, at doses of 
58 mg/100 mL and 100.3 ± 12.8 mg/100 g, respectively. 
In the final stage of 16 weeks of treatment was observed 
that the APE-treated group presented elevated choles-
terol level and LDL in serum, while the BGJ group pre-
sented a reduction in VLDL. Both groups presented 
elevation of SOD, beside the APE group elevated the glu-
tathione peroxidase (GPx) level. There was no reduction 
in cholesterol accumulation the aorta of either group. The 
treatment with purified anthocyanin and black goose-
berry juice presents conflicting results, suggesting further 
investigations to prove the results.
Kabiri et al. [170] studied regression in a rabbit model. 
The animals were submitted to protocol of hypercho-
lesterolemic diet during 45  days, after they received 
supplementation of A. caudatus extract (150  mg/kg/
dia), associated with normal diet, during 30  days. The 
A. caudatus extracts, considered an excellent source of 
anthocyanin and fibers, led to a meaningful regression 
of atherosclerosis area and decrease of total cholesterol, 
LDL, MDA and PCR levels in serum. In comparison with 
the control group, the treated group also had an eleva-
tion of apolipoprotein and HDL-cholesterol, showing 
an effectiveness antioxidant activity. The supplementa-
tion with A. caudatus extract decrease the risk factors to 
CVD, due the hypercholesterolemic diet. Abdel-Moemin 
[171] also had positive results in the increase of HDL-C 
and lower hydroperoxides and thiobarbituric reactive 
substances concentrations when was used the treatment 
with black rice (25 g for 10 weeks).
Hypercholesterolemic rabbits were also used as a 
model by Sozański et  al. [172] to evaluate the effects of 
the components of cornelian cherries on lipid metabo-
lism, augmentation of protein PPARα, lipid peroxida-
tion and antioxidants. During 60  days, rabbits were 
exposed to standard diet plus 1% of cholesterol. The 
experimental groups were exposed to lyophilized diet of 
cornelian cherry compounds (100  mg/kg). After experi-
mental diet, the results demonstrated that triglycerides 
level were diminished (44%) in treated animals compared 
to hypercholesterolemic control. Level of LDL and ath-
erogenic index in plasma also were reduced in these 
treated animals, although it was not significant to cardiac 
risk and atherogenic coefficient in relation to control. The 
expression of PPARα and GSH activity were elevated, 
SOD and GPx levels did not show difference. Thus, they 
suggested that the lipid peroxidation in the liver was 
diminished, due to inclusion of cornelian cherry to the 
diet.
Human studies involving anthocyanins in cardiovascular 
diseases
Several human studies have confirmed the findings found 
in animal models, although the literature remains con-
troversial [169, 170]. Alvarez-Suarez et  al. [64] treated 
health humans with fresh anthocyanin rich fruit. The 
participants should had cycles of dietary consump-
tion of strawberry; they were advised to avoid straw-
berry and other polyphenols. After these 10  days, the 
patients received the strawberry for 30 days 500 g daily, 
and blood and urinary samples were collect. At the end 
of the 30 days, the patients were recommended to avoid 
strawberry for more 15  days. After these periods, again 
blood and urinary samples were collect to analyze. The 
results demonstrated that after strawberry-supplemented 
patients presented decreased levels of cholesterol, LDL 
and triglyceride. These parameters returned to baseline 
levels after 15  days of the strawberry supplementation. 
The study also showed lower levels of spontaneous and 
oxidative hemolysis. Thus, these authors concluded that 
the strawberry rich diet could partially protect the pre-
vention of CVD.
Qin et  al. [173] used capsules containing 17 purified 
anthocyanins from bilberry (Vaccinium myrtillus) and 
black currant (Ribes nigrum) on 120 subjects, divided in 
two groups, one taking two 80-mg anthocyanin capsules 
twice a day (320 mg/day) and the other using two placebo 
capsules twice a day. The patients were submitted to the 
treatment for 12 weeks. Blood parameters were measure 
before and after the period of 12  weeks with a fasting 
overnight. In the blood analysis was observed increase 
of HDL-cholesterol and cholesterol efflux in serum in 
anthocyanin group compared to placebo. In contrast, 
the LHL-cholesterol and plasma cholesteryl ester protein 
(CETP) were decreased in the Anthocyanin group cor-
related to placebo. In this study, the authors suggested 
that the decrease of LHL and increase of HDL is related 
the inhibition of the CETP. In other studies of this same 
group, using the same extract they also showed similar 
results to LDL and HDL, and they observed a significant 
increase of HDL-associated esterase/lactonase paraoxo-
nase 1 (HDL-PON1), plasma cGMP and flow-mediated 
dilation. Thus, they concluded that the PON1 activity as 
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associated to a better efflux of cholesterol and of cGMP, 
which can lead to improvement of the endothelium-
dependent vasodilation through the activation of the 
NO-cGMP signaling pathway [174, 175].
Using the same anthocyanin-purified extract, Hassel-
lund et al. [176] conducted an experiment similar to that 
designed by Qin et  al. [173] but over a shorter period 
of time. They used 27 subjects divided in two groups, a 
control placebo and the treated group. The patients in 
the treated group received a daily intake of 640 mg of the 
purified extract for 4 weeks followed by a washout period 
of 4 weeks. Those patients were physically examined after 
those period of time, including oscillometric blood pres-
sure measurements, laboratory assessments, also doing 
stress tests, the both cold pressor test and mental stress 
test. The extract treated group presented no significant 
difference in the blood pressure and stress reactivity 
levels in relation to the control group. This group also 
performed a similar study, using the same posology and 
the same extract, with 31 subjects with blood pressure 
of 4140/90  mmHg without use of anti-hypertensive or 
lipid-lowering medication. This research analyzed com-
mon CVD markers and markers for oxidative stress. They 
stated that the HDL-cholesterol was modest increased in 
the patients treated with anthocyanin.
Using an elderberry (Sambucus nigra) extract that con-
tained 125 mg of anthocyanin, Curtis et al. [65] analyzed 
whether this extract had an effect on CVD biomarkers in 
post-menopausal women. This study involved 52 volun-
teers and they were separate in two groups, control and 
elderberry extract treated. They used a dose of 500 mg/
day of the extract for 12  weeks. The participants had 
blood samples collect to verify the CVD biomarkers; they 
also analyzed kidney and liver function, to access safety. 
The treated group showed no significant changes in the 
cardiac biomarkers, neither in the liver and renal func-
tion. This data proved that the extract was safe however 
ineffective in altering the CVD biomarkers the period of 
the study [65].
In a study on blueberry, Basu et al. [177] used 66 obese 
patients with metabolic syndrome. The study included 
men and women. The patients were divided in two group; 
one group was treated with 50  g of freeze-dried blue-
berry dissolved and reconstituted in 480 mL of water and 
vanilla. In the control group, the patients were advised to 
consume water as control. The patients were treated for 
8 weeks with an evaluation after each 4-week period. This 
evaluation consisted of anthropometric and blood pres-
sure measurements, the assessment of dietary intake and 
fasting blood draws. The data showed a more significant 
reduction in blood pressure, oxLDL and serum MDA and 
hydroxynonenal; serum glucose concentration and lipid 
profiles showed no significant alteration. These results 
suggest that blueberries have a correlation with CVD 
markers and improve aspects of metabolic syndrome.
Basu et  al. [178]. also investigated cranberry juice 
in a placebo-controlled trial. In this study, the authors 
observed changes in TEAC, oxLDL, MDA, inflamma-
tory biomarkers (PCR, interleukin-6) and lipid profiles 
for subjects with metabolic syndrome. According to their 
finds, cranberry juice-treated patients had increased 
plasma antioxidant capacity, decreased oxiLDL and 
decreased MDA. However, in relation to PCR and inter-
leukin-6, no significant alteration was observed in either 
group. Another study based on cranberry juice was per-
formed by Dohadwala et  al. [179]. The authors inves-
tigated the effect of cranberry juice in subjects with 
coronary artery disease. In this crossover study, all sub-
jects were submitted to noninvasive methods to examine 
the effect of cranberry juice on various measures of vas-
cular function. The data showed decreased aortic stiff-
ness in comparison to the placebo group.
Another important study was the one performed by 
Cassidy et  al. [180] in which were correlated the nutri-
tional information about the habitual intake of flavonoids 
and the risks of development of CVDs from 43,880 men 
aged from 32 to 81 during 24 years. This research showed 
that habitual intakes as high as 613 mg/day of anthocya-
nins could be correlated to a 14% lower risk of develop-
ment of nonfatal myocardial infarction in men, the same 
correlation was found in women before [181, 182].
In a double-blind study Naruszewicz et  al. [183] 
used chokeberry extract to 44 patients with mean age 
of 66  years (11 women and 33 men) were treated three 
time a day with 85  mg/day after survival of myocar-
dial infraction, the results shown the reduction of some 
CVD’s markers compared with the placebo group, such 
as 8-isoprostanes, oxLDL, hsCRP and MCP-1. The study 
also stated a decrease in blood pressure and adiponectin 
levels. Other studies have shown that chokeberry extract 
have capacity of reduction of SOD and platelet aggrega-
tion levels, lower arterial blood pressure and decrease 
inflammation in atherosclerosis [66, 183–185]. The data 
collected are presented in Fig. 3.
Conclusion
The bioactive compounds found in some plants produce 
positive effects that have been used in the medicinal field 
as potent new drugs for the treatment of several dis-
eases, including CVD. This review showed that this fact 
remains true for the use of anthocyanins as potent drugs 
for the prevention of CVD due to inhibition the inflam-
matory process, the endothelial dysfunction and vasodi-
lators production. Therefore, the major proposed action 
mechanisms of fruits/flowers extracts or isolates antho-
cyanins are antioxidant action (capturing free radicals 
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and/or anions, inhibiting XO, chelating metal ions, tar-
geting arachidonic acid and NF-κB, TNF-α pathways and 
adhesion molecules), suppression of the NO production 
and induction of Nrf2 transcription triggering heme oxy-
genase-1 expression. Human intervention studies and 
animal models using berries, vegetables, parts of plants 
and cereals (either fresh or as juice) or purified anthocya-
nin-rich extracts have demonstrated significant improve-
ments in LDL oxidation, VLDL, CRP, Total Triglycerides, 
MDA, as well as, decreasing comorbidities. Also, improv-
ing the clinical states of patients with CVD, showing that 
animal studies and humans trials have been successful in 
demonstrating the efficacy of anthocyanins to prevent 
and improve the life quality of CVD patients. Despite of 
the potential benefit, there is still a need to standardize 
therapeutic strategies, such as appropriate effective dose, 
treatment time and relevant clinical laboratory parame-
ters, which will allow the use of a large number of juice or 
purified anthocyanin-rich extracts as treatment or com-
plement to existing treatment of CVD.
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